Team - Laboratory of Pharmacology of Dyslipidemias and Atherosclerosis
Phone +390250318328Medical Biotechnologist, PhD in Molecular and Translational Medicine and specialization in Medical Pharmacology. I have gained expertise in the development and characterization of experimental disease models, primarily in the cardiovascular field. My research activity is focused on the impact of gut microbiota on host pathophysiology, particularly on lipid/lipoprotein metabolism and atherosclerosis development.
Biotechnologist, with a solid background in molecular biology, cell culture, biochemical assays and advanced statistical analysis in Python, gained in more than 10 years in R&D labs in the Academy, both in Italy and abroad. Current research topics include repurposed drugs and gut microbiota. Involved in the design, drafting and writing of research projects, as well as in their management. Graduated with honors and with a PhD, author of several scientific publications.
Phone +390250319913Alice Ossoli is a post-doctoral fellow at DISFEB since 2015. In 2014 she received the doctorate in Pharmacological Sciences at the Università degli Studi di Milano. Part of her research activity has conducted at the Lipoprotein metabolism lab of NIH headed by Dr. Remaley. The main research activities include the understanding of the atheroprotective and cardioprotective properties of HDL and the study of renal disease caused by lipoprotein alterations in LCAT deficiency.
Phone +390250319910Chiara Pavanello is a post-doctoral fellow at DISFEB, where she is involved in the study of rare diseases of lipid metabolism. From 2015 to 2018 she worked as a PhD student at Centro E. Grossi Paoletti, under the supervision of Prof. Laura Calabresi, with a project about atherosclerosis in genetic LCAT deficiency. Part of her PhD project was developed at the University Medical Center of Amsterdam, headed by Prof. Stroes, where she focused on the immune aspect of genetic HDL disorders.
Phone +390250319913Sara Simonelli is a post-doctoral fellow at DISFEB since 2012. She holds a PhD in Applied Morphobiology and Drug Cytometabolism at the Università degli Studi di Bari. The main research activity aims to evaluate the effect of new compounds on LCAT activity, to identify new potential drug for prevention and treatment of atherosclerotic cardiovascular diseases.
Phone +390250319905Eleonora Giorgio is a PhD student at “Centro Enrica Grossi Paoletti” at DiSFeB. After her master’s degree, she had a scholarship at CEGP, where she is currently carrying out her PhD program, under the supervision of Dr. Monica Gomaraschi. Her research is about the antitumoral properties of HDL in prostate cancer models.
Phone +390250319913Arianna Strazzella is a PhD student at DISFEB. She worked as an undergraduate student at “Centro E. Grossi Paoletti”, under the supervision of Prof. Calabresi, then in 2018 she started her PhD program in the same lab. Her researches are focused on the study of renal disease induced by lipoprotein alterations in LCATdeficiency and on the study of atheroprotective and cardioprotective properties of HDL.
Alessandra D’Agostina contributes to the research activity of the Centro E. Grossi Paoletti. Her main activity is the characterization of plasma lipoproteins in patients who had myocardial infarction through chromatographic techniques.